Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation specific PCR (MSP) assay was used for determining the methylation status of CpG island of p16 and MGMT genes in CRC patients.
|
31004929 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Somatic epigenetic inactivation of the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT) is frequent in colorectal cancer (CRC); however, its involvement in CRC predisposition remains unexplored.
|
30677446 |
2019 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The impact of the common functional polymorphism of the catechol-O-methyltransferase (COMT) gene, Val158Met, on promoter hypermethylation of P16 and MGMT genes in CRC was also investigated.
|
30379684 |
2019 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The methylation frequencies of MGMT gene promoter were 41.4%, 34.2%, and 44.2% in stomach, esophageal, and colorectal cancer cases while as 16.6, 13.3, and 13.3 in respective controls.
|
28135856 |
2017 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This was a multicentre, phase 2 trial, planned according to a two-stage Simon's optimal design to investigate activity and safety of temozolomide in refractory CRC harbouring MGMT promoter methylation.
|
28427088 |
2017 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hierarchical clustering isolated three relevant clusters: (i) cluster of microsatellite stable mucinous adenocarcinomas (54%) with KRAS mutation, and frequent MGMT changes, more frequently located in the left colon, often associated with contiguous precursor adenoma; (ii) cluster of BRAF-mutated mucinous adenocarcinomas (28%) with either microsatellite instability-high or microsatellite stable status, occurring in elderly female patients, nearly all located in the right colon, having the signature of serrated pathway of carcinomas; and (iii) a heterogeneous cluster of microsatellite instability-high mucinous carcinomas (18%), including inherited colorectal carcinomas, displaying a high-grade histological pattern.
|
28429715 |
2017 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rate of MGMT protein loss was low in metastatic CRC patients from China, and MGMT might be more commonly lost in signet ring cell carcinoma.
|
27006309 |
2016 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Secreted frizzled related protein 2 (SFRP2), APC1A in WNT signaling pathway and the DNA repair gene, O6-methylguanine-DNA methyltransferase (MGMT), are frequently hypermethylated in colorectal cancer.
|
27221916 |
2016 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We provide evidence that rs16906252C>T is associated with elevated risk for MGMT-methylated colorectal cancer, likely mediated by constitutive epigenetic repression of the T allele.
|
27267851 |
2016 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter in CRC patients was more frequently methylated than in adenoma patients.
|
25596081 |
2015 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT hypermethylation is found to be significantly higher in CRC than in normal colorectal mucosa, the pooled OR from 13 studies including 1085 CRC and 899 normal colorectal mucosa, OR = 6.04, 95 % confidence interval (CI) = 4.69-7.77, p < 0.00001.
|
25716203 |
2015 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Somatic hypermethylation of the O6-methylguanine-DNA methyltransferase gene (MGMT) was previously associated with G > A transition mutations in KRAS and TP53 in colorectal cancer (CRC).
|
25638164 |
2015 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors.
|
25832877 |
2015 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The advanced stage patients with p16, hMLH1, and MGMT methylation were associated with higher risk of CRC recurrence compared with the local stage patients with unmethylation status in tumor tissues, with adjusted hazard ratios (HRs) (95% confidence interval [CI]) of 9.64 (2.92-31.81), 8.29 (3.40-20.22), and 11.83 (3.49-40.12), respectively.
|
25815725 |
2015 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We applied artificial neural networks (ANNs) to understand the connections among polymorphisms of genes involved in folate metabolism, clinico-pathological features and promoter methylation levels of MLH1, APC, CDKN2A(INK4A), MGMT and RASSF1A in 83 sporadic colorectal cancer (CRC) tissues, and to link dietary and lifestyle factors with gene promoter methylation.
|
25942531 |
2015 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to evaluate the activity of temozolomide in terms of response rate in patients with metastatic CRC and MGMT methylation, after failure of approved treatments.
|
24379162 |
2014 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, this meta-analysis suggests that the PARP-1 rs1136410: T > C polymorphism is a susceptibility factor for GI cancers, but the variant allele of MGMT rs12917: C > T polymorphism appears to be a protective factor for colorectal cancer.
|
24203816 |
2014 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in MGMT play a critical role in the development of several types of cancer, including glioblastoma, lung cancer, and colorectal cancer.
|
24801985 |
2014 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to determine the prognostic value of CD133 and MGMT and their possible interaction in colorectal cancer patients.
|
25015560 |
2014 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alkylating agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O(6)-guanine site, inducing base pair mismatch; therefore, activity of dacarbazine could be enhanced in CRCs lacking MGMT.
|
23422094 |
2013 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Nineteen percent of the screened population (137/740) had confirmed tissue and/or serum MGMT promoter methylation, including 25% (57 of 229) for CRC, 36% (55 of 154) for esophageal cancer, 11% (12 of 113) for head and neck cancer, and 5% (13 of 242) for non-small cell lung carcinoma.
|
23443801 |
2013 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
To identify which CpG sites are critical for its downregulation, we analyzed the methylation status of the MGMT gene promoter in two sites in CRC patients.
|
23271133 |
2013 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In line with these studies, MGMT was linked to the formation of human sporadic CRC.
|
23929436 |
2013 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
O(6)-CMG is therefore an MGMT substrate, and hence MGMT is likely to be a protective factor in CRC under conditions where O(6)-CMG is a potential causative agent.
|
23335782 |
2013 |
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This study evaluated the role of Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation together/independently in sporadic CRC in Indian population and correlation with clinicopathological variables of the disease.
|
23573237 |
2013 |